Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "steroids"

48 News Found

Biocon partner Equillium initiates clinical study for Itolizumab in Lupus Nephritis
Biotech | December 24, 2021

Biocon partner Equillium initiates clinical study for Itolizumab in Lupus Nephritis

Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000


Amneal gets approval for Difluprednate ophthalmic emulsion
Drug Approval | November 22, 2021

Amneal gets approval for Difluprednate ophthalmic emulsion

The company is moving towards complex and more differentiated products


Alarming rise in diabetes amongst children and adolescents in India
News | November 14, 2021

Alarming rise in diabetes amongst children and adolescents in India

The rise in cases amongst the young is a cause for concern. A few specialists gave us a perspective on the issue


U.S. FDA expands approval of Dupixent to include children aged 6 to 11 years
Drug Approval | October 22, 2021

U.S. FDA expands approval of Dupixent to include children aged 6 to 11 years

Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option


Health Minister Mansukh Mandaviya releases post-Covid sequelae modules
Public Health | September 23, 2021

Health Minister Mansukh Mandaviya releases post-Covid sequelae modules

These modules will act as a guide to doctors and health care workers to deal with post-Covid-19 issues


DGCI approves Hetero’s Tocilizumab
Drug Approval | September 06, 2021

DGCI approves Hetero’s Tocilizumab

Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month


Sanofi’s Dupixent pivotal trial meets all primary and secondary endpoints for treatment of atopic dermatitis
Biotech | August 31, 2021

Sanofi’s Dupixent pivotal trial meets all primary and secondary endpoints for treatment of atopic dermatitis

Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old


Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b in treating COVID-19
News | April 05, 2021

Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b in treating COVID-19

PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents